PMV Pharmaceuticals planeja submissão de NDA do rezatapopt no 1T 2027

A PMV concluiu o recrutamento de pacientes com câncer de ovário resistente/refratário a platina para a análise primária na porção de monoterapia da Fase 2 do ensaio PYNNACLE. A empresa agora planeja submeter um NDA para aprovação acelerada do rezatapopt nesta indicação no primeiro trimestre de 2027.

Fatos principais

Arquivado: 14 de ago. de 2026, 12:00
Evento: Pedido submetido
Direção: Neutro
Empresa: PMVPPMV Pharmaceuticals
Ativo: rezatapopt
Fonte: SEC 8-K
Confiança: Com fonte

Trecho da fonte

EX-99.1 2 pmvp-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights • Enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE clinical trial completed • Rezatapopt NDA submission for platinum-resistant/refractory ovarian cancer planned in first quarter of 2027 • Cash, cash equivalents, and marketable securities of $79.4 million as of June 30, 2026 providing expected cash runway through second quarter of 2027 PRINCETON, N.J., August 14, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule t

SEC 8-K